What is Avrobio Financial Strength?
Avrobio has the Financial Strength Rank of 8. It shows strong financial strength and is unlikely to fall into distressed situations.
Good Sign:
Avrobio Inc shows strong financial strength.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its
Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3.
Altman Z-Score.
Avrobio has no long-term debt (1).
As of today, Avrobio's Altman Z-Score is 0.00.
(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Competitive Comparison of Avrobio's Financial Strength
For the Biotechnology subindustry, Avrobio's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Avrobio's Financial Strength Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Avrobio's Financial Strength distribution charts can be found below:
* The bar in red indicates where Avrobio's Financial Strength falls into.
Avrobio Financial Strength Calculation
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Avrobio's Interest Expense for the
months ended in Dec. 2023 was $0.00 Mil. Its Operating Income for the
months ended in Dec. 2023 was $-9.63 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil.
Avrobio's Interest Coverage for the quarter that ended in Dec. 2023 is
| Avrobio had no long-term debt (1). |
The higher the ratio, the stronger the company's financial strength is.
2. Debt to revenue ratio. The lower, the better.
Avrobio's Debt to Revenue Ratio for the quarter that ended in Dec. 2023 is
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
Avrobio has a Z-score of 0.00, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avrobio (Avrobio) Business Description
Traded in Other Exchanges
N/A
Address
100 Technology Square, Sixth Floor, Cambridge, MA, USA, 02139
Avrobio Inc is a clinical-stage gene therapy company. It is engaged in developing potentially curative ex vivo lentiviral gene therapies to treat rare diseases following a single dose treatment regimen. The company's pipeline includes AVR-RD-04 for the treatment of cystinosis; AVR-RD-02 for the treatment of Gaucher disease type 1; AVR-RD-05 for the treatment of Hunter syndrome; AVR-RD-06 for the treatment of Gaucher disease type 3; and AVR-RD-03 for the treatment of Pompe disease.
Executives
| Azadeh Golipour |
officer: Chief Technology Officer |
ONE KENDALL SQUARE, BLD. 300 - SUITE 201, CAMBRIDGE MA 02139 |
| Essra Ridha |
officer: Chief Medical Officer |
C/O AVROBIO, INC., ONE KENDALL SQUARE, BLDG 300 - SUITE 201, CAMBRIDGE MA 02139 |
| Philip J. Vickers |
director |
C/O REVANCE THERAPEUTICS, INC., 7555 GATEWAY BOULEVARD, NEWARK CA 94560 |
| Christopher Mason |
officer: Chief Scientific Officer |
C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203 |
| Phillip B. Donenberg |
director |
C/O AVEXIS, INC., 2275 HALF DAY ROAD, SUITE 200, BANNOCKBURN IL 60015 |
| Diana Escolar |
officer: Chief Medical Officer |
C/O MIRAGEN THERAPEUTICS, INC., 6200 LOOKOUT ROAD, BOULDER CO 80301 |
| Gail M Farfel |
director |
142 TEMPLE STREET, SUITE 205, NEW HAVEN CT 06510 |
| Deanna M Petersen |
officer: Chief Business Officer |
45 FIRST AVENUE, WALTHAM MA 02451 |
| Geoffrey Mackay |
director, officer: See Remarks |
C/O AVROBIO, INC., ONE KENDALL SQ, BLDG. 300, STE. 201, CAMBRIDGE MA 02139 |
| Christopher Paige |
director |
C/O AVROBIO INC, ONE KENDALL SQ, BLDG 300, STE 201, CAMBRIDGE MA 02139 |
| Atlas Venture Fund X, L.p. |
10 percent owner |
400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139 |
| Atlas Venture Associates Opportunity I, Llc |
other: See Remarks |
400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139 |
| Atlas Venture Associates Opportunity I, L.p. |
other: See Remarks |
400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139 |
| Atlas Venture Opportunity Fund I, L.p. |
other: See Remarks |
400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139 |
| Bruce Booth |
director |
890 WINTER STREET, SUITE 320, WALTHAM MA 02451 |
Avrobio (Avrobio) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AVRO has been successfully added to your